SkinCure Oncology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $10M

Overview

SkinCure Oncology, founded in 2017, commercializes Image-Guided Superficial Radiation Therapy (IG-SRT) as a patient-friendly, non-surgical treatment for non-melanoma skin cancers like basal cell and squamous cell carcinoma. The company operates a partnership-based business model, equipping and supporting dermatology practices across the US to offer this technology, thereby expanding patient access to an effective alternative with a reported 99%+ cure rate and high patient satisfaction. As of early 2026, SkinCure Oncology reports treating over 140,000 patients across more than 380 partner practices in 48 states, indicating rapid commercial adoption and scale.

OncologyDermatology

Technology Platform

Image-Guided Superficial Radiation Therapy (IG-SRT) - A non-invasive radiation therapy system that uses real-time imaging (e.g., ultrasound) to guide and customize radiation dose for the treatment of non-melanoma skin cancer.

Funding History

1

Total raised:$10M

Series A$10MUndisclosedJun 15, 2018

Opportunities

The massive and growing incidence of non-melanoma skin cancer, driven by an aging population, creates a vast addressable market.

There is significant opportunity to capture patients seeking a non-surgical alternative to Mohs, as well as to deepen penetration within existing large dermatology networks and expand into adjacent specialties.

Risk Factors

Key risks include changes to Medicare and private insurance reimbursement rates for SRT procedures, which could cripple the economic model for partner practices.

The company also faces competition from the entrenched standard of care (Mohs surgery) and potential new non-invasive technologies, while bearing the operational complexity of managing a distributed network of devices and personnel.

Competitive Landscape

SkinCure Oncology's primary competitor is Mohs micrographic surgery, the gold-standard surgical treatment performed by dermatologic surgeons. Other competitors include traditional superficial radiation therapy (without image guidance), cryosurgery, topical therapies, and emerging systemic therapies for advanced cases. The company differentiates through its integrated image-guidance, comprehensive in-office support model, and strong focus on patient experience.

More companies in Oncology (General) →More companies in United States →